Number of shares and votes in Calliditas Therapeutics

Rhea-AI Summary

Calliditas Therapeutics AB announced the issuance of 7,500 common shares in January 2023, linked to its long-term incentive program for 2019/2022. Post-issuance, the total number of shares and corresponding votes reached 59,580,087. This adjustment reflects ongoing efforts to align employee incentives with company performance. Calliditas is a biopharma company focused on developing treatments for orphan diseases, particularly in renal and hepatic fields. Its lead product, Nefecon, has received FDA accelerated approval as TARPEYO and conditional marketing authorization in Europe as Kinpeygo. The information was disclosed in compliance with the Swedish Financial Instruments Trading Act.

Positive

• Successful issuance of 7,500 shares indicates active employee incentive alignment.
• Total share count now stands at 59,580,087, reflecting company growth.

Negative

• None.

STOCKHOLM, Jan. 31, 2023 /PRNewswire/ -- During January, Calliditas Therapeutics AB (publ) has issued 7,500 common shares connected to the company's long term incentive program 2019/2022. Thus, as of January 31, 2023, the number of shares and votes in the company amounts to 59,580,087 shares and 59,580,087 votes.

For further information, please contact:

Mikael Widell, Investor relations

Tel.: +46 703 11 99 60, email: mikael.widell@calliditas.com

The information in the press release is such that Calliditas Therapeutics AB (publ) is required to disclose pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 CET on January 31, 2023.

About Calliditas

Calliditas Therapeutics is a commercial stage biopharma company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas' lead product, developed under the name Nefecon, has been granted accelerated approval by the FDA under the trade name TARPEYO^® and conditional marketing authorization by the European Commission under the trade name Kinpeygo^®. Additionally, Calliditas is conducting a Phase 2b/3 clinical trial in primary biliary cholangitis and a Phase 2 proof-of-concept trial in head and neck cancer with its NOX inhibitor product candidate, setanaxib. Calliditas' common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT).

The following files are available for download:

https://mb.cision.com/Main/16574/3705881/1815153.pdf

Number of shares and votes January 2023 (Eng)

View original content:https://www.prnewswire.com/news-releases/number-of-shares-and-votes-in-calliditas-therapeutics-301734370.html

SOURCE Calliditas Therapeutics

FAQ

What was the share issuance by Calliditas Therapeutics in January 2023?

In January 2023, Calliditas Therapeutics issued 7,500 common shares as part of its long-term incentive program.

What is the total number of shares and votes for Calliditas Therapeutics as of January 31, 2023?

As of January 31, 2023, Calliditas Therapeutics has 59,580,087 shares and votes.

What is the significance of the share issuance for Calliditas Therapeutics?

The issuance of shares is intended to align employee incentives with the company's performance.

What are the main products of Calliditas Therapeutics?

Calliditas's lead product, Nefecon, has FDA accelerated approval as TARPEYO and EU conditional marketing authorization as Kinpeygo.